Dr Winnie Lam Wing Chuen

With two decades of specialist experience, Winnie has actively contributed to the development of novel PET imaging applications across oncology, neuroimaging, and systemic inflammatory diseases. Her leadership in education, as the inaugural Program Director of the Singapore Nuclear Medicine Residency, and her long-standing service on national training and advisory committees highlight her influence in shaping the next generation of medical specialists. Winnie has led and participated in multiple clinical trials involving advanced molecular tracers (e.g. FET, FAPI, PSMA, Y-90), and her recent publications reflect strong expertise in theranostics and quantitative imaging. Her current interest will be advancing low-dose, high-sensitivity imaging platforms and guiding clinical validation in patients through her dual focus on precision theranostics and operational excellence.

• Fellow of the Academy of Medicine, Singapore in Nuclear Medicine
• Fellow of the Royal College of Radiologists (UK)
• MBBS, National University of Singapore

• Clinical Trialist Development Award, SingHealth Duke-NUS Joint Office of Academic Medicine 2025
• Faculty Appreciation Award, Residency in SingHealth Excels (RiSE) 2019
• RADSC ACP Sponsorship Award, EANM 2018
• Best JCST Programme (Nuclear Medicine), Residency in SingHealth Excels (RiSE) 2018
• Silver Award, Team Excellence IQC Assessment, Singapore Productivity Association 2016
• Outstanding Faculty Award, Residency in SingHealth Excels (RiSE) 2014

• Telix study for Glioblastoma (TLX-101-003) (PI)
• AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer (PI)
• 18F-FET (O-(2-[18F]fluoroethyl)-L-tyrosine) PET in differentiating tumour progression from pseudoprogression in high grade gliomas (PI)
• 68Ga-FAPI based PET/CT for imaging Systemic sclerosis-associated Interstitial Lung Disease (SSc-ILD) (Co-Investigator)
• Outcomes of Radioiodine Therapy for Thyroid Cancer (PI)

• The Present and Future of THERANOSTICS. W. W.-C.Lam, S. P.Thang, K. S.-H.Loke, et al. Asia-Pacific Journal of Clinical Oncology (2026). doi.org/10.1111/ajco.70126
• Real World Outcomes of Prescribed Ablative Dose Yttrium-90 Resin Selective Internal Radiation Therapy of Hepatocellular Carcinoma. Koo SX, Poh YK, Too NSH, Chua WM, Lim DSW, Goh CXY, Lam WWC, Loke KSH, Tong AKT. World J Nucl Med. 2026 Jul. DOI: 10.1055/s-0046-1825760.
• Cost-effectiveness analysis of a biopsy-free diagnostic strategy for prostate cancer using mpMRI and PSMA-PET/CT. Tung JYM, Lau RS-E, Teo EPS, Chow KM, Ong JHW, Lu TS, Chen W, Li J, Yang X, Lee AY, Tan YG, Tay KJ, Thang SP, Lam WWC, Law YM, Ho HSS, Cheng CWS, Yuen JS, Chen K. BJUI Compass. 2026;7(2):e70172. doi.org/10.1002/bco2.70172
• Exploratory evaluation of early 68Ga-FAPI-46 PET/CT volume-based parameters in systemic sclerosis-associated interstitial lung disease. Tai SB, Chua WM, Ng CWQ, Noviani M, Tham WP, Saffari SE, Lam WWC, Ng DCE, Low ASCS, Xie W, Low AHL. Eur J Nucl Med Mol Imaging (2026). doi.org/10.1007/s00259-025-07710-4
• Do you Really Want to Know—Attitudes of Physicians and English-Proficient Asian Patients toward Direct Release of Radiology Reports in Singapore. Chian, D.MG., Liauw, L., Chua, S.L. Chan LP, Cook TS, Goh CX, Lam WWC, Chua WM, Lim KC. J Digit Imaging. Inform. med. (2025). doi.org/10.1007/s10278-025-01655-8
• Theranostics and Molecular Imaging are taking off- current situation, requirements and how to train more physicians to fill the gap. A perspective from three different continents. Veit-Haibach P, Lam W, Wong RKS, Cook GJR. Br J Radiol. 2025 Sep 25:tqaf243. doi: 10.1093/bjr/tqaf243. PMID: 40996318.
• Bayesian Penalized Likelihood Reconstruction Algorithm Results in Similar Prognostic Markers on FDG PET/CT in DLBCL. Huang HL, Koo SX, Tang C, Tham WY, Zaheer S, Lam W, Chan JYS. Hematological Oncology 2025 Jun.
• Combined Prostate-specific Membrane Antigen Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. Chow KM, Lee A, Peh D, Tan YG, Tay KJ, Ho H, Cheng C, Lam W, Thang SP, Tuan J, Law YM, NgoT, Khor LY, Yuen J, Eapen R, Lawrentschuk N, Hofman M, Murphy D, Chen K. European Urology Oncology 2025 Jun.
• Safety and Efficacy of Lutetium-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study). Ng CWQ, Chua WM, Lam WW, Tong AK, Ng DCE, Tang C, Tham WY, Kanesvaran R, Wong ASC, Tay KJ, Chen K, Thang SP. Asia Pac J Clin Oncol. 2025 May.
• Prognostic [68Ga]Ga-PSMA-11 PET Biomarkers for [177Lu]Lu-PSMA Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer (Asian Population Study). Koh NXY, Chua WM, Lam WW, Tong AK, Kanesvaran R, Wong ASC, Chen K, Thang SP. Asia Pac J Clin Oncol. 2025 Aug;21(4);399-406.
• Differentiated Thyroid Cancer after Thyroidectomy. Chua WM, Tang CYL, Loke KSH, Lam WW, Yang SP, Lee MS, Hou W, Lim WYS, Lim KC, Chen R. Radiographics. 2024 Oct;44(10):e240021.